Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
出版年份 2021 全文链接
标题
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
作者
关键词
Coronavirus, COVID-19, Delta, Efficacy, Review, SARS-CoV-2, Seroneutralization, Vaccines, Variants
出版物
CLINICAL MICROBIOLOGY AND INFECTION
Volume 28, Issue 2, Pages 202-221
出版商
Elsevier BV
发表日期
2021-10-27
DOI
10.1016/j.cmi.2021.10.005
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021
- (2021) et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
- (2021) Piyada Supasa et al. CELL
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
- (2021) Wilfredo F. Garcia-Beltran et al. CELL
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
- (2021) Merryn Voysey et al. LANCET
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- (2021) Denis Y Logunov et al. LANCET
- Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
- (2021) Dami A. Collier et al. NATURE
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
- (2021) Zijun Wang et al. NATURE
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
- (2021) Constantinos Kurt Wibmer et al. NATURE MEDICINE
- Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
- (2021) Xuping Xie et al. NATURE MEDICINE
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
- (2021) Noa Dagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
- (2021) Florian Krammer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralizing Activity of BNT162b2-Elicited Serum
- (2021) Yang Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
- (2021) Nicholas G. Davies et al. SCIENCE
- Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
- (2021) Robert Challen et al. BMJ-British Medical Journal
- SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
- (2021) Markus Hoffmann et al. CELL
- Antibody evasion by the P.1 strain of SARS-CoV-2
- (2021) Wanwisa Dejnirattisai et al. CELL
- Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
- (2021) Venkata Viswanadh Edara et al. Cell Host & Microbe
- Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees
- (2021) Pragya D Yadav et al. CLINICAL INFECTIOUS DISEASES
- The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data
- (2021) Gabriel Chodick et al. CLINICAL INFECTIOUS DISEASES
- Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021
- (2021) Massimo Fabiani et al. Eurosurveillance
- Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination
- (2021) Venkata Viswanadh Edara et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
- (2021) Brian J. Boyarsky et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers
- (2021) Yoel Angel et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce
- (2021) Li Tang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- BNT162b2 mRNA Covid-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection: a preliminary report
- (2021) Francesco Paolo Bianchi et al. JOURNAL OF INFECTIOUS DISEASES
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
- (2021) Eric J Haas et al. LANCET
- Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
- (2021) Robert H Shaw et al. LANCET
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
- (2021) Katherine R W Emary et al. LANCET
- SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity
- (2021) Muthukumar Ramanathan et al. LANCET INFECTIOUS DISEASES
- Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
- (2021) Leticia Monin et al. LANCET ONCOLOGY
- Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
- (2021) Sandile Cele et al. NATURE
- Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
- (2021) Delphine Planas et al. NATURE MEDICINE
- Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine
- (2021) Matan Levine-Tiefenbrun et al. NATURE MEDICINE
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
- (2021) Tom T. Shimabukuro et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
- (2021) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
- (2021) Xiaoying Shen et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Antibody Response in Persons with Past Natural Infection
- (2021) Gabriele Anichini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
- (2021) Yaniv Lustig et al. NEW ENGLAND JOURNAL OF MEDICINE
- Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
- (2021) Guo-Lin Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
- (2021) Yang Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Shabir A. Madhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
- (2021) Nicole Doria-Rose et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Vivek Shinde et al. NEW ENGLAND JOURNAL OF MEDICINE
- mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
- (2021) Leonidas Stamatatos et al. SCIENCE
- Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
- (2021) Nuno R. Faria et al. SCIENCE
- Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
- (2021) Jamie Lopez Bernal et al. BMJ-British Medical Journal
- Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
- (2021) Mark W. Tenforde et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination
- (2021) Rishi R. Goel et al. Science Immunology
- SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting
- (2021) Adeel A. Butt et al. ANNALS OF INTERNAL MEDICINE
- Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
- (2021) Chang Liu et al. CELL
- Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021
- (2021) Finlay Campbell et al. Eurosurveillance
- Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
- (2021) Elina Seppälä et al. Eurosurveillance
- Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses
- (2021) Ilies Benotmane et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Surveillance for Adverse Events After COVID-19 mRNA Vaccination
- (2021) Nicola P. Klein et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults
- (2021) Nawal Al Kaabi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A cluster of the new SARS‐CoV‐2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine
- (2021) Serena Messali et al. JOURNAL OF MEDICAL VIROLOGY
- Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
- (2021) Xinxue Liu et al. LANCET
- SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
- (2021) Aziz Sheikh et al. LANCET
- Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
- (2021) Mine Durusu Tanriover et al. LANCET
- Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
- (2021) Yuxin Chen et al. LANCET INFECTIOUS DISEASES
- BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
- (2021) Jianying Liu et al. NATURE
- BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
- (2021) Ugur Sahin et al. NATURE
- mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
- (2021) Hiam Chemaitelly et al. NATURE MEDICINE
- Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy
- (2021) Noa Dagan et al. NATURE MEDICINE
- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
- (2021) Angela Choi et al. NATURE MEDICINE
- Effect of Vaccination on Transmission of SARS-CoV-2
- (2021) Anoop S.V. Shah et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
- (2021) Alejandro Jara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
- (2021) Robert W. Frenck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
- (2021) Paul T. Heath et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel
- (2021) Tamara Pilishvili et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Vaccination on Household Transmission of SARS-CoV-2 in England
- (2021) Ross J. Harris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
- (2021) Victoria G. Hall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion
- (2021) Lauren H. Zauche et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- (2021) Ann R. Falsey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce
- (2021) Jocelyn Keehner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
- (2021) Yinon M. Bar-On et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
- (2021) Venkata-Viswanadh Edara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
- (2021) Noam Barda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
- (2021) Mark G. Thompson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
- (2021) Hana M. El Sahly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
- (2021) Stephen J. Thomas et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
- (2021) Matthew McCallum et al. SCIENCE
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
- (2021) Amarendra Pegu et al. SCIENCE
- Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
- (2021) Donal T. Skelly et al. Nature Communications
- SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021
- (2021) Jennifer B. Griffin et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
- (2021) Eli S. Rosenberg et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021
- (2021) Ashley Fowlkes et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021
- (2021) Catherine M. Brown et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
- (2021) Julia W. Gargano et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021
- (2021) Shaun J. Grannis et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021
- (2021) Wesley H. Self et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines
- (2021) Osama Abu-Hammad et al. Vaccines
- Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants
- (2021) Vladimir A. Gushchin et al. Vaccines
- Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study
- (2021) Hind B. Almufty et al. Diabetes & Metabolic Syndrome-Clinical Research & Reviews
- High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers
- (2021) R. Palich et al. ANNALS OF ONCOLOGY
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
- (2021) Sara Y Tartof et al. LANCET
- Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis
- (2020) John Allotey et al. BMJ-British Medical Journal
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2
- (2020) Lucy van Dorp et al. Nature Communications
- History of vaccination
- (2014) S. Plotkin PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More